prostate cancer
Let an agent explain prostate cancer in general terms, relay risk factors, screening debates, staging and treatment options from oncology guidelines with attribution, describe the rarer forms the registry aliases name, and distinguish prostate cancer from benign prostatic hyperplasia and prostatitis, routing anyone with symptoms or a diagnosis to their clinicians.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify
Researched by: Claude
Purpose and description
Let an agent explain prostate cancer in general terms, relay risk factors, screening debates, staging and treatment options from oncology guidelines with attribution, describe the rarer forms the registry aliases name, and distinguish prostate cancer from benign prostatic hyperplasia and prostatitis, routing anyone with symptoms or a diagnosis to their clinicians.
A cancer arising in the prostate gland, most often an adenocarcinoma, one of the most common cancers in men, often slow-growing and detected by PSA testing and biopsy, with rarer forms including neuroendocrine neoplasms, lymphoma and phyllodes tumours of the prostate, familial prostate cancer linked to inherited variants, and metastasis to the prostate from other cancers; treatment ranges from active surveillance to surgery, radiotherapy and hormonal therapy. The model gives general information and routes people to clinicians.
What it is for: Not applicable; a disease.
It can be explain the disease; relay screening and treatment; route to clinicians; distinguish related conditions.
Distinguishing features
Common in older men
Often slow-growing
PSA screening debate
Range of treatments
What it looks like
Not a visible object; a tumour in the prostate.
Physical character
new cases worldwide: about 1.4 million - 2020, GLOBOCAN
median age at diagnosis: about 67 years
5-year survival, localised: near 100 percent - high-income countries
Gleason grading: grade groups 1-5 note
How it is recognised
Cancer of the prostate gland
Prostate carcinoma, familial prostate cancer, neuroendocrine neoplasm, lymphoma, phyllodes tumour, metastasis to prostate
Benign prostatic hyperplasia is non-cancerous enlargement; prostatitis is inflammation
Related models
is a kind of - in registry terms
is a kind of - in registry terms
is detected by - and biopsy
is contrasted with - non-cancerous enlargement
In practice
Families and kinds
prostate adenocarcinoma
familial and hereditary prostate cancer
neuroendocrine prostate cancer
prostate lymphoma and sarcoma
phyllodes tumour of the prostate
metastases to the prostate
Identifiers
ICD-10 C61 malignant neoplasm of prostate
MeSH D011471 Prostatic Neoplasms
Standards and regulation
Oncology guidelines such as NCCN, EAU and NICE
Screening recommendations by national bodies
Failure modes and hazards
Agents giving personal medical advice
Overdiagnosis and overtreatment debates
Registry aliases mixing rare tumour types
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.
Understand What prostate cancer is.
Clinical.
Definition
Definition.
Definition
Definition.
- What is prostate cancer, and how does it differ from benign hyperplasia and prostatitis? definition
- Is the user describing personal symptoms or a diagnosis, which needs their clinician? boundary
Types
Types.
Types
Types.
- What are adenocarcinoma, familial, neuroendocrine, lymphoma and phyllodes forms and metastases to the prostate? definition
- Which entry fits the specific type? action
Detection Screening and diagnosis.
Attribution.
Screening
Screening.
Screening
Screening.
- What do guidelines say about PSA screening, and what is debated, with positions attributed? provenance
- Which references are standard? provenance
Diagnosis
Diagnosis and staging.
Diagnosis
Diagnosis.
- How are biopsy, MRI, Gleason grading and staging used? provenance
- Which sources are cited? provenance
Treatment Treatment.
Clinical.
Options
Options.
Options
Options.
- What are active surveillance, surgery, radiotherapy, hormonal and systemic therapies, in general terms? provenance
- Which entry fits the specific treatment? action
Living
Living with the disease.
Living
Living.
- What support and follow-up exist, as patient organisations describe? provenance
- Which entry fits cancer survivorship? action
Context Research and epidemiology.
Context.
Epidemiology
Epidemiology.
Epidemiology
Epidemiology.
- What are the risk factors and global patterns? provenance
- Which entry fits cancer epidemiology? action
Research
Research.
Research
Research.
- What are current research directions, such as genomics and new therapies? provenance
- Which entry fits oncology research? action
What the second pass must settle
- Should the rare tumour types be separate primary entries?
- How should oncology guidelines be linked?
- The registry entry has merged aliases naming rare forms and metastases; should they be split off?